HANK & LIN'S GROUP

The past is prologue and the future is scintillating

68Ga-P15-041

Introduction to [68Ga]Ga-P15-041 (68Ga-HBED-CC-BP)：

        [68Ga]Ga-P15-041, also known as 68Ga-HBED-CC-BP, is an advanced bone-seeking PET radiotracer developed for the detection of bone metastases. It is composed of gallium-68 (68Ga), the HBED-CC chelator, and a bisphosphonate (BP) moiety, which grants it a high affinity for bone mineralization sites.

A key advantage of [68Ga]Ga-P15-041 is its straightforward preparation process. The 68Ga isotope can be conveniently sourced from an in-house 68Ga/68Ge generator, and the tracer can be formulated using a simple kit, making it more accessible for clinical use. Currently in clinical research, [68Ga]Ga-P15-041 has demonstrated strong imaging performance, positioning it as a promising alternative to existing bone-targeting radiopharmaceuticals.

        [68Ga]Ga-P15-041 is a highly promising PET imaging agent for detecting bone metastases, offering high bone uptake, excellent sensitivity, and rapid imaging capabilities. Its potential as a superior alternative to [18F]NaF and [99mTc]Tc-MDP makes it a valuable addition to nuclear medicine.

Publications：

  1. Guo, R., Meng, X., Wang, F., Yu, J., Xie, Q., Zhao, W., Zhu, L., Kung, H. F., Yang, Z., & Li, N. (2021). 68Ga-P15-041, A Novel Bone Imaging Agent for Diagnosis of Bone Metastases. Frontiers in oncology, 11, 766851. https://doi.org/10.3389/fonc.2021.766851.
  2. Hong, H., et al. "Development and validation of a kit formulation of [68Ga]Ga-P15-041 as a bone imaging agent". Applied Radiation and Isotopes, 2021 169, p.109485. https://doi.org/10.1016/j.apradiso.2020.109485
  3. Doot, R.K., et al. "Biodistribution, dosimetry, and temporal signal-to-noise ratio analyses of normal and cancer uptake of [68Ga]Ga-P15-041, a gallium-68 labeled bisphosphonate, from first-in-human studies". Nuclear Medicine and Biology. 2020 (86-87):1-8. https://doi.org/10.1016/j.nucmedbio.2020.04.002
  4. Zha, Z., et al. "A new [68Ga]Ga-HBED-CC-bisphosphonate as a bone imaging agent". Molecular Pharmaceutics. 2020 17 (5), 1674-1684. https://doi.org/10.1021/acs.molpharmaceut.0c00103

Meeting Abstracts：

  1. Alexoff, D., et al. "A rapid prototyping platform for radiochemistry automation: experience with Ga-68 labeling." Journal of Nuclear Medicine 59, no. supplement 1 (2018): 1037.
  2. 6. Margaret, D., et al. "Investigation of acquisition strategies for [68Ga] P15-041 bone imaging in prostate cancer." Journal of Nuclear Medicine 59, no. supplement 1 (2018): 1094.
  3. 7.Hong, H., et al. "A simple kit-based preparation of [Ga-68] Ga-P15-041: A novel bone imaging agent". JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (Vol. 62, pp. S272-S273，2019).
  4. 8.Alexoff, D., et al. "Preliminary kinetic analysis of [68Ga] P15-041, a novel 68Ga labeled bisphosphonate, from first-in-human studies." Journal of Nuclear Medicine 58, no. supplement 1 (2017): 388.
  5. 9.Hank Kung. New 68ga hbed-bisphosponates and their derivatives as bone imaging agents.Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1106;
  6. Wang J, Wang G, Li L, Zhu Z, Zhu L, Kung HF. A prospective head-to-head comparison of [68Ga] Ga-HBED-CC-BP and [68Ga] Ga-PSMA-11 PET/CT in patients with bone metastases from prostate cancer. Journal of Nuclear MedicineJune 2023,64(supplement 1)P967;